Through our interface, industry and academic partners seamlessly access unique and diverse resources for curing diseases of the pancreas.

The PBRU in Liverpool has worked with companies to develop and validate a broad range of healthcare products including new therapeutics (small molecules, antibodies, vaccines and gene therapies), diagnostic methodologies (PET/CT Imaging, confocal endoscopy and laparoscopy). The PBRU is able to expertly work with companies of all sizes and in various application areas. Examples of companies we have worked with include: 












Clinical Trials Services


Clinical trials services for pancreas-related research are provided by the Clinical Research Facility (CRF) within the Royal Liverpool Hospital.

 In addition, to facilities and infrastructure the PCRF is able to design, lead, conduct, and support high quality clinical trials, systematic reviews and other well-designed clinical studies.

 With respect to development of new therapeutics the PCRF is able to support the clinical development of new therapeutics from the phase I/II evaluation of the safety and efficacy of new therapeutics to late phase III efficacy studies.

 Analysis of clinical trials samples for relevant biomarkers can be performed to GCLP standards using validated bioassays.  Pharmacological considerations (pharmacokinetics, pharmacogenetics, pharmacogenomics and pharmacological proteomics) can be addressed through the PBRU partners.

Studies to support the validation of diagnostic strategies and surgical and device interventions are also catered for.

Examples of commercial clinical trials carried out by the Liverpool Pancreas BRU include:

                MetXia - Study of efficacy of MetXia-OB83 and cyclophosphamide in patients undergoing palliative surgery for adenocarcinoma of the head of the pancreas.

                KAbi - Open, randomised phase I/II dose escalation study evaluating the safety and tolerability, pharmacokinetics, antigenicity and efficacy of Iodine-131-Kab201 when given intra-arterially or intravenously in patients with surgically unresectable pancreatic ductal adenocarcinoma.

                PN144 - Evaluation of PET/CT for monitoring chemotherapy response in pancreatic cancer. A multi-centre study involving Manchester, Cambridge, London and Liverpool, with the PBRU GCLP facility acting as the central laboratory for processing samples from all centres participating in the trial.

                TeloVac - Prospective, phase III, controlled, open label, multi-centre, randomised clinical trial comparing combination Gemcitabine and Capecitabine therapy with concurrent and sequential immunotherapy using the telomerase vaccine GV1001 (Telovac) in locally advanced and metastatic pancreatic cancer.

                A6181114 - Open-Label Sunitinib Malate (SU011248) continuation protocol for patients who have completed a prior Sunitinib study and are judged by the investigator to have the potential to benefit from Sunitinib treatment.

Research Services


The Liverpool PBRU is also the first point of contact for basic and pre-clinical research needs with respect to the pancreas.

Areas we are able to support include:

 •              Drug screening in cell-based assays

              Drug screening in models of disease

              Biomarker discovery and validation

              Proteomic analysis

              Pharmacogenetic analysis

              Understanding of disease or drug mechanisms

              Optimisation of chemical leads

              Drug-induced pancreatitis

However, we can work with companies to tailor a programme of research to suit individual needs, and where appropriate coordinate access to broader resources in Liverpool.

To access facilities, expertise and unique resources such as models of disease, patient registries and the PBRU biobank through collaborations or under service contract, please contact the PBRU team.